[Articles] 8 weeks versus 12 weeks of sofosbuvir–velpatasvir for treatment-naive, non-cirrhotic, chronic hepatitis C (RESOLVE): a multicentre, open-label, non-inferiority, randomised controlled trial in India

Data Readoutpositivesofosbuvir–velpatasvirPositive

AI Analysis

Summary

A randomized controlled trial in India demonstrated that an 8-week regimen of sofosbuvir–velpatasvir is non-inferior to the standard 12-week treatment for treatment-naive patients with non-cirrhotic chronic hepatitis C, potentially supporting shortened treatment duration.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

8-week regimen showed non-inferiority to standard 12-week treatment in treatment-naive, non-cirrhotic patients with chronic HCV

Importance:6/10

Sentiment:

0.70

hepatitis Csofosbuvir–velpatasvirclinical trialnon-inferioritytreatment duration

Read the original article

Published by The Lancet on September 30, 2026 10:30 PM

Read Original